Sufrin G, Mink I, Fitzpatrick J, Moore R, Murphy G P
J Urol. 1978 Jun;119(6):727-30. doi: 10.1016/s0022-5347(17)57612-0.
Coagulation factors, including plasma fibrinogen, serum fibrinogen-fibrin degradation products, platelet counts and prothrombin times, were studied in patients with renal adenocarcinoma. Plasma fibrinogen levels were elevated and correlated with tumor stage, disease activity and therapy. Fibrinogen-fibrin degradation product levels also were elevated, although such elevations did not correlate with other parameters. Platelet count and prothrombin times were normal. Fibrinogen may be a valuable marker of disease activity in patients with renal carcinoma. In addition, since significant intratumoral fibrin deposits have been demonstrated anticoagulants or fibrinolytic agents may enhance cytotoxic therapy and should be considered in adjunctive chemotherapeutic protocols.
对肾腺癌患者的凝血因子进行了研究，包括血浆纤维蛋白原、血清纤维蛋白原 - 纤维蛋白降解产物、血小板计数和凝血酶原时间。血浆纤维蛋白原水平升高，且与肿瘤分期、疾病活动度及治疗相关。纤维蛋白原 - 纤维蛋白降解产物水平也升高，尽管这种升高与其他参数无关。血小板计数和凝血酶原时间正常。纤维蛋白原可能是肾癌患者疾病活动度的一个有价值的标志物。此外，由于已证实在肿瘤内有大量纤维蛋白沉积，抗凝剂或纤溶药物可能会增强细胞毒性治疗，应在辅助化疗方案中予以考虑。
